Denmark’s MinervaX raises €54M to prevent life-threatening infections caused by Group B streptococcus

Denmark-based biotechnology company MinervaX ApS announced the completion of a €54M upsized financing. MinervaX aims to use the funding to boost the development of a novel prophylactic vaccine against Group B Streptococcus, or GBS.

The vaccine’s development is critical as GBS is a leading cause of life-threatening infections in newborns and adverse pregnancy outcomes. Available prophylactic measures are insufficient against GBS, which spurs the urgent need to develop a new GBS vaccine.

This financing will enable MinervaX to develop its novel GBS vaccine towards Phase III clinical trials in 2024. 

The funding included investment from new investors EQT Life Sciences and Orbimed. Existing investors Novo Holdings, Pureos Ventures, Sanofi Ventures, Trill Impact Ventures, Adjuvant Capital, Wellington Partners, Industrifonden, Sunstone LifeScience Ventures, and LF Invest, also participated in this round.